Look back at pharma news in week to October 12

By Barbara Obstoj-Cardwell. Editor

Regulatory news of interest last week included the US Food and Drug Administration’s approval of Akcea Therapeutics rare disease drug Tegsedi, but it came with a black box warning, and FDA acceptance of Karyopharm’s selinexor New Drug Application for multiple myeloma. On the deal making front, there was Roche's agreement to access Ionis Pharmaceuticals’ age-related macular degeneration research program, while in terms of drug trials, safety concerns caused Affimed to discontinue its AFM11 leukemia study.

Tegsedi gets US Green light, but still looks second best